Anavex Life Sciences Corp (AVXL)

[investor300]

If you read the most recent presentation before conference you should not have had expectations of seeing 15 week results.

Catalysts in 2017 (slide #38 of March 2017 Corporate Presentation)

- Granted Orphan Drug Designations for the following indications: Rett Syndrome, Infantile spams and Frontotemporal dementia (CHECKED)
- Phase 2a – Report PART B 57 week data at CTAD scientific meeting (CHECKED)
- Phase 2a – Updates on 104 week extension Alzheimer’s study
- Phase 2a – Report PK/PD data
- Initiate Phase 2 clinical trial in Rett Syndrome (12 week, randomized, double-blind, placebo controlled)
- Initiate Phase 2 clinical trial in Parkinson’s (12 week, randomized, double-blind, placebo controlled)
- Initiate Phase 2/3 clinical trial in Alzheimer’s (6/12 month, randomized, double-blind, placebo controlled)
- Potential for clinical read-out by end 2017 / early 2018